Anne M. Traynor, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Traynor is an Associate Professor of Medicine in the Section of Medical Oncology in the UW Carbone Cancer Center. She specializes in the care of patients with lung cancer and in patients with head and neck malignancies. Dr. Traynor obtained an undergraduate degree in Chemical Engineering from North Carolina State University and medical degree from the University of North Carolina. She completed her residency and chief residency in internal medicine at the Mary Imogene Bassett Hospital in Cooperstown, NY. Dr. Traynor obtained her Fellowship training in medical oncology from the University of Iowa Hospitals and Clinics, and participated in the UW Carbone Cancer Center Academic Clinical Oncologist Training Program. She has been on faculty at the UW Carbone Cancer Center since 2002.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of Iowa Hospital and Clinics, Iowa City, IA
Mary Imogene Bassett Hospital and Clinics, Cooperstown, NY
University of North Carolina School of Medicine, Chapel Hill, NC
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Programs & Conditions
Dr. Traynor leads the lung cancer research program within the UW Department of Medicine, and is the Co-Director for the Thoracic Malignancies Research Group for the UW Carbone Cancer Center. She conducts clinical trials testing new compounds in lung cancer and in early phase drug development. She collaborates with laboratory scientists in lung cancer-related translational research projects, such as examining molecular causes or resistance to radiation and systemic anti-cancer agents. Since 2003, Dr. Traynor has led the Wisconsin Oncology Network, a statewide medical oncology research group that conducts phase II clinical trials at the UW Carbone Cancer Center and at 17 other regional sites. She chairs the UW Carbone Cancer Center Data and Safety Monitoring Committee and represents the Cancer Center in several federal oncology research organizations.
Fenske TS Shah NM Kim KM Saha S Zhang C Baim AE Farnen JP Onitilo AA Blank JH Ahuja H Wassenaar T Qamar R Mansky P Traynor AM Mattison RJ Kahl BS .
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. Cancer. 2015 Jun 16;
[PubMed ID: 26079295]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK .
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol. 2015 Jun 12;
[PubMed ID: 26068189]
Nyflot MJ Kruser TJ Traynor AM Khuntia D Yang DT Hartig GK McCulloch TM Wiederholt PA Gentry LR Hoang T Jeraj R Harari PM .
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):942-51
[PubMed ID: 25659884]
Boggs DH Robins HI Langer CJ Traynor AM Berkowitz MJ Mehta MP .
Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer. 2014 Nov;15(6):433-40
[PubMed ID: 25069747]
Rajguru S Kristinsdottir T Eickhoff J Peterson C Meyer CM Traynor AM Kahl BS .
Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol. 2014 Aug;12(8):509-15
[PubMed ID: 25356575]
Cannon DM Geye HM Hartig GK Traynor AM Hoang T McCulloch TM Wiederholt PA Chappell RJ Harari PM .
Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck. 2014 Aug;36(8):1120-5
[PubMed ID: 23804248]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH .
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2014 Jul 1;
[PubMed ID: 24986793]
Weichert JP Clark PA Kandela IK Vaccaro AM Clarke W Longino MA Pinchuk AN Farhoud M Swanson KI Floberg JM Grudzinski J Titz B Traynor AM Chen HE Hall LT Pazoles CJ Pickhardt PJ Kuo JS .
Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014 Jun 11;6(240):240ra75
[PubMed ID: 24920661]
Burkard ME Wisinski KB Njiaju UO Donohue S Hegeman R Stella A Mansky P Shah V Goggins T Qamar R Dietrich L Kim K Traynor AM Tevaarwerk AJ .
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer. 2014 Jun;14(3):205-11
[PubMed ID: 24342730]
Mirrielees JA Kapur JH Szalkucki LM Harter JM Salkowski LR Strigel RM Traynor AM Wilke LG .
Metastasis of primary lung carcinoma to the breast: a systematic review of the literature. J Surg Res. 2014 May 15;188(2):419-31
[PubMed ID: 24560348]
Bible KC Suman VJ Molina JR Smallridge RC Maples WJ Menefee ME Rubin J Karlin N Sideras K Morris JC 3rd McIver B Hay I Fatourechi V Burton JK Webster KP Bieber C Traynor AM Flynn PJ Cher Goh B Isham CR Harris P Erlichman C .
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May;99(5):1687-93
[PubMed ID: 24606083]
Schelman WR Mohammed TA Traynor AM Kolesar JM Marnocha RM Eickhoff J Keppen M Alberti DB Wilding G Takebe N Liu G .
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr;32(2):295-302
[PubMed ID: 23860642]
Hoang T Campbell TC Zhang C Kim K Kolesar JM Oettel KR Blank JH Robinson EG Ahuja HG Kirschling RJ Johnson PH Huie MS Wims ME Larson MM Hernan HR Traynor AM .
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs. 2014 Feb;32(1):195-9
[PubMed ID: 23728919]
Casavant BP Strotman LN Tokar JJ Thiede SM Traynor AM Ferguson JS Lang JM Beebe DJ .
Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform. Lab Chip. 2014 Jan 7;14(1):99-105
[PubMed ID: 24158597]
Schelman WR Traynor AM Holen KD Kolesar JM Attia S Hoang T Eickhoff J Jiang Z Alberti D Marnocha R Reid JM Ames MM McGovern RM Espinoza-Delgado I Wright JJ Wilding G Bailey HH .
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec;31(6):1539-46
[PubMed ID: 24114121]
Cannon DM Mehta MP Adkison JB Khuntia D Traynor AM Tomé WA Chappell RJ Tolakanahalli R Mohindra P Bentzen SM Cannon GM .
Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4343-8
[PubMed ID: 24145340]
Kolesar JM Traynor AM Holen KD Hoang T Seo S Kim K Alberti D Espinoza-Delgado I Wright JJ Wilding G Bailey HH Schelman WR .
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7
[PubMed ID: 23903894]
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ .
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Traynor AM Weigel TL Oettel KR Yang DT Zhang C Kim K Salgia R Iida M Brand TM Hoang T Campbell TC Hernan HR Wheeler DL .
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul;81(1):138-41
[PubMed ID: 23628526]
Iida M Brand TM Campbell DA Starr MM Luthar N Traynor AM Wheeler DL .
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther. 2013 Jun;14(6):481-91
[PubMed ID: 23760490]